BioMarin Pharmaceutical's Stock Price Expectations Shift Amid Voxzogo Risks and Amicus Acquisition

BioMarin Pharmaceutical's (BMRN) price targets now range from $50 to over $100 on Wall Street, driven by different readings of Voxzogo's long-term potential, the planned Amicus acquisition, and the broader rare disease portfolio and pipeline. Analysts have set targets in the $90 to $105 range, citing optimism around Amicus and Voxzogo label expansion opportunities. However, some firms, including H.C. Wainwright, have cut targets due to competitive pressure on Voxzogo and potential rival launches.